HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.
Also called NCT04556851
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 476 participants
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
- Registry
-
NCT04556851
-
- Other papers using this trial's data
- Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04556851. Randomized; double masking; primary purpose treatment. Start 2020-09-29 (actual); primary completion 2022-01-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- HSK7653 10 mg Q2W
- Intervention (Drug)
- HSK7653 25 mg Q2W
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Record details
- Record id
cardio:ct-nct04556851- Content hash
b67e678e9455e5c829e0450facba144f671ac9ef06b0283c07a98aa244edd3e6